Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-11-22

FDA Approved: BUPRENORPHINE TRANSDERMAL SYSTEM — Supplemental Application (Alvogen Inc.)

View source ↗

Summary

The FDA approved a supplemental application for the Buprenorphine Transdermal System by Alvogen Inc. (buprenorphine transdermal patch).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BUPRENORPHINE TRANSDERMAL SYSTEM (buprenorphine)

Snippet

SUPPL AP for BUPRENORPHINE TRANSDERMAL SYSTEM (BUPRENORPHINE)